Evaluation of anesthetic technique on surgical site infections (SSIs) at a single institution.

C. Curry,Kahsi A. Smith,J. Allyn

DOI: https://doi.org/10.1016/j.jclinane.2014.04.015

IF: 9.375

2014-12-01

Journal of Clinical Anesthesia

Abstract:

What problem does this paper attempt to address?

A Nomogram and Risk Stratification System for Predicting Survival in T1-2N0-1 Breast Cancer Patients with Liver Metastasis in Females: a Population-Based Study

Kaiyue Wang,Lu Shen,Yiding Chen,Zhe Tang

DOI: https://doi.org/10.1186/s12938-024-01274-4

2024-01-01

BioMedical Engineering OnLine

Abstract:Liver was one of the most common distant metastatic sites in breast cancer. Patients with distant metastasis were identified as American Joint Committee on Cancer (AJCC) stage IV indicating poor prognosis. However, few studies have predicted the survival in females with T1-2N0-1 breast cancer who developed liver metastasis. This study aimed to explore the clinical features of these patients and establish a nomogram to predict their overall survival. 1923 patients were randomly divided into training (n = 1154) and validation (n = 769) cohorts. Univariate and multivariate analysis showed that age, marital status, race, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), chemotherapy, surgery and bone metastasis, brain metastasis were considered the independent prognostic indicators. We developed a nomogram according to these ten parameters. The consistency index (c-index) was 0.72 (95
Development and Validation of Nomograms for Predicting Overall and Breast Cancer–Specific Survival in Young Women with Breast Cancer: A Population-Based Study

Yue Gong,Peng Ji,Wei Sun,Yi-Zhou Jiang,Xin Hu,Zhi-Ming Shao

DOI: https://doi.org/10.1016/j.tranon.2018.08.008

IF: 4.803

2018-01-01

Translational Oncology

Abstract:INTRODUCTION: The objective of current study was to develop and validate comprehensive nomograms for predicting the survival of young women with breast cancer. METHODS: Women aged <40 years diagnosed with invasive breast cancer between 1990 and 2010 were selected from the Surveillance, Epidemiology, and End Results database and randomly divided into training (n = 12,465) and validation (n = 12,424) cohorts. A competing-risks model was used to estimate the probability of breast cancer–specific survival (BCSS). We identified and integrated significant prognostic factors for overall survival (OS) and BCSS to construct nomograms. The performance of the nomograms was assessed with respect to calibration, discrimination, and risk group stratification. RESULTS: The entire cohort comprised 24,889 patients. The 5- and 10-year probabilities of breast cancer–specific mortality were 11.6% and 20.5%, respectively. Eight independent prognostic factors for both OS and BCSS were identified and integrated for the construction of the nomograms. The calibration curves showed optimal agreement between the predicted and observed probabilities. The C-indexes of the nomograms in the training cohort were higher than those of the TNM staging system for predicting OS (0.724 vs 0.694; P < .001) and BCSS (0.733 vs 0.702; P < .001). Additionally, significant differences in survival were observed in patients stratified into different risk groups within respective TNM categories. CONCLUSIONS: We developed and validated novel nomograms that can accurately predict OS and BCSS in young women with breast cancer. These nomograms may help clinicians in making decisions on an individualized basis.
Establishment and Verification of Prognostic Nomograms for Young Women with Breast Cancer Bone Metastasis

Zhan Wang,Haiyu Shao,Qiang Xu,Yongguang Wang,Yaojing Ma,Diarra Mohamed Diaty,Jiahao Zhang,Zhaoming Ye

DOI: https://doi.org/10.3389/fmed.2022.840024

IF: 3.9

2022-01-01

Frontiers in Medicine

Abstract:PurposeThe prognosis of patients with metastatic breast cancer usually varies greatly among individuals. At present, the application of nomogram is very popular in metastatic tumors. The present study was conducted to identify independent survival predictors and construct nomograms among young women with breast cancer bone metastasis (BCBM).Patients and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database to identify young women diagnosed with BCBM between 2010 and 2016. We first analyzed the potential risk factors of overall survival (OS) and cancer-specific survival (CSS) by applying univariate Cox regression analysis. Then we conducted multivariate Cox analysis to identify independent survival predictors. Based on significant independent predictors, we developed and validated novel prognostic nomograms by using the R version 4.1.0 software.ResultsWe finally identified 715 eligible young women with BCBM for survival analysis, of which 358 patients were in the training set, and 357 patients in the validation set. Approximately four-fifths of patients are between 31 and 40 years old. The 5-year OS and CSS rates of this research population were 41.9 and 43.3%, respectively. Multivariate analysis revealed seven independent predictors of both OS and CSS, including race, tumor subtype, tumor size, surgical treatment, brain metastasis, liver metastasis, and lung metastasis. Based on these predictors, we developed and validated OS and CSS nomograms. The C-index of the OS nomogram reached 0.728 and 0.73 in the training and validation sets, respectively. The C-index of the CSS nomogram reached 0.743 and 0.695 in the training and validation sets, respectively. Meanwhile, high quality calibration plots were revealed in both OS and CSS nomograms.ConclusionThe current novel nomograms can provide an individualized survival evaluation of young women with BCBM and instruct clinicians to treat them appropriately.
Nomograms predict survival in elderly women with triple-negative breast cancer: A SEER population-based study

Ruigang Feng,Wenwen Huang,Bowen Liu,Dan Li,Jinlai Zhao,Yue Yu,Xuchen Cao,Xin Wang

DOI: https://doi.org/10.3233/thc-231240

IF: 1.6

2024-02-03

Technology and Health Care

Abstract:BACKGROUND: The effective treatment of breast cancer in elderly patients remains a major challenge. OBJECTIVE: To construct a nomogram affecting the overall survival of triple-negative breast cancer (TNBC) and establish a survival risk prediction model. METHODS: A total of 5317 TPBC patients with negative expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) who were diagnosed and received systematic treatment from 2010 to 2015 were collected from the American Cancer Surveillance, Epidemiology and End Results (SEER) database. They were randomly divided into training set (n= 3721) and validation set (n= 1596). Univariate and multivariate Cox regression analysis were used to identify prognostic features, and a nomogram was established to predict the probability of 1-year, 3-year and 5-year OS and BCSS. We used consistency index (C-index), calibration curve, area under the curve (AUC) and decision curve analysis (DCA) to evaluate the predictive performance and clinical utility of the nomogram. RESULTS: The C-indices of the nomograms for OS and BCSS in the training cohort were 0.797 and 0.825, respectively, whereas those in the validation cohort were 0.795 and 0.818, respectively. The receiver operating characteristic (ROC) curves had higher sensitivity at all specificity values as compared with the Tumor Node Metastasis (TNM) system. The calibration plot revealed a satisfactory relationship between survival rates and predicted outcomes in both the training and validation cohorts. DCA demonstrated that the nomogram had clinical utility when compared with the TNM staging system. CONCLUSION: This study provides information on population-based clinical characteristics and prognostic factors for patients with triple-negative breast cancer, and constructs a reliable and accurate prognostic nomogram.

engineering, biomedical,health care sciences & services
Development and Validation of Nomograms for Predicting Overall and Cancer-Specific Survival in Young Patients with Non-Small Cell Lung Cancer

Yizhou Peng,Yihua Sun

DOI: https://doi.org/10.21037/jtd.2020.03.03

2020-01-01

Journal of Thoracic Disease

Abstract:Background: Young patients with non-small cell lung cancer (NSCLC) represent a distinct subgroup of patients with this disease. This study aimed to construct nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of young patients with NSCLC. Methods: NSCLC patients under 50 years old diagnosed between 2010 and 2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database and randomly divided into training (n=1,357) and validation ( n=678) cohorts at a ratio of 2:1. Independent prognostic factors for OS or CSS were identified through the log-rank test, Cox proportional hazards models or competing risk model and further integrated to construct nomograms. The predictive capability of the nomogram was assessed by Harrell's concordance index (C-index), the calibration curve and risk group stratification. Results: A total of 2,035 patients were enrolled. In the training cohort, insurance, marital status, histological type, grade, T stage, N stage and surgery were identified as independent prognostic for OS and CSS. The C-index value were 0.759 [95% confidence interval (CI): 0.731-0.787] for OS and 0.810 (95% CI: 0.803-0.818) for BCSS in the training cohort and 0.751 (95% CI: 0.711-0.790) for OS and 0.807 (95% CI: 0.795-0.819) for CSS in the validation cohort. The calibration curves showed optimal agreement between the predicted and actual survival both in internal and external validation. In addition, patients in the validation cohort within different risk groups exhibited significantly different survival even in each TNM stage. Conclusions: Nomograms were developed and validated to predict OS and CSS of young patients with NSCLC in our study. A prospective study with more potential prognostic factors and the latest TNM classification is required to ameliorate this model.
Overall survival and disease‐free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms

Ruigang Feng,Wenwen Huang,Jie Min,Wenjun Shu,Yanshou Zhang,Yue Yu,Xuchen Cao,Xin Wang

DOI: https://doi.org/10.1111/jep.14157

2024-10-15

Journal of Evaluation in Clinical Practice

Abstract:Purpose By analyzing the existing data of this study, a prediction tool for the overall breast cancer survival and disease‐free survival (DFS) of elderly women was established. Patients and Methods Clinicopathologic data were collected from elderly women with BC who were admitted to the Tianjin Medical University Cancer Institute and Hospital from August 2014 to December 2017. Independent prognostic factors for BC in elderly patients were confirmed using the Cox proportional hazards model. Nomograms were developed with these factors for predicting the 3‐ and 5‐year overall survival (OS) as well as DFS. The nomograms' discrimination ability and calibration were assessed through the area under the curve (AUC), concordance index (C‐index), decision curve analysis (DCA), and calibration plots. Results We enroled 889 elderly patients with BC, and the results showed that the 3‐year OS rate was 93.4% (95%CI = 91.8%–95.1%), the 3‐year DFS rate was 87.8% (95%CI = 85.7%–90.0%), the 5‐year OS rate was 85.6% (95%CI = 83.3%–87.9%), and the 5‐year DFS rate was 80.1%(95%CI = 77.5%–82.8%). The corrected C‐indices of the OS and DFS nomograms were 0.799 and 0.667, respectively (95%CI = 0.767–0.830 and 0.632–0.702, respectively). Relatively high AUC values were shown by the nomograms for estimating OS and DFS. The DCA revealed that the constructed nomograms had net benefits for clinical application. The calibration curves demonstrated an excellent correspondence between the data predicted by the nomograms and the actual survival data. Survival curves indicated that risk stratification could differentiate OS and DFS. Conclusions This study developed novel and practical nomograms for individual prediction of DFS and OS in elderly BC patients. These nomograms can predict 3‐ and 5‐year OS as well as DFS in the elderly BC patient population, thereby enabling personalized risk assessment and risk‐based therapy.

medicine, general & internal,health care sciences & services,medical informatics
Nomogram for Predicting Survival in Triple-Negative Breast Cancer Patients with Histology of Infiltrating Duct Carcinoma: a Population-Based Study.

Dongjun Dai,Hongchuan Jin,Xian Wang

2018-01-01

Abstract:Triple-negative breast cancer (TNBC) represents around 15%-20% of newly diagnosed breast cancer and is more aggressive than other breast cancer sub-types. Infiltrating duct carcinoma (IDC) is the most common type of TNBC. Nomogram is a valuable tool for prognosis prediction by integrating different biological and clinical variables. The purpose of current study was to evaluate the prognostic value of clinical factors of TNBC patients with IDC histology type and construct nomograms for their outcome prediction. The cohort was selected from Surveillance, Epidemiology, and End Results (SEER) program. Univariate and multivariate analyses were performed using Cox proportional hazards regression model to evaluate the prognostic value of involved variables. Nomogram was constructed from the multivariate logistic regression model to combine all the prognostic factors to predict the 1-year and 3-year prognosis of TNBC patients with histology of IDC. Internal validation of nomogram was tested by discrimination and calibration. We identified 14,538 patients with the median and max survival time was 28 months and 59 months, respectively. There were 1,592 deaths, accounting for 10.9% of the cohort. Multivariate analyses showed that grade, tumor stage, tumor size, regional nodes positive, marital status, experience of radiotherapy or chemotherapy were independent prognostic factors of IDC of TNBC. Eleven variables were combined to construct 1-year and 3-year nomograms. It was revealed that the C-index of the nomograms was 0.763 and the calibration curves showed good agreement between the nomogram prediction and actual observation. Current study was the first one to construct nomograms of TNBC patients with IDC histology, which could help physicians to identify patients at high risk for intensive treatment or follow-up.
Novel Nomograms to Predict of Overall Survival and Cancer-specific Survival of Patients of Metaplastic Breast Cancer

Yongfeng Li,Daobao Chen,Haojun Xuan,Mihnea P. Dragomir,George A. Calin,Hongjian Yang,Meng Chen,hongchuan Jin

DOI: https://doi.org/10.21203/rs.3.rs-96114/v1

2020-01-01

Abstract:Abstract Background Metaplastic breast cancer (MBC) is a rare type of breast cancer with an increasing incidence, we aim to develop clinical nomograms to predict the overall survival and cancer-specific survival for patients with MBC.MethodsPatients data were collected from the SEER database between 1973 and 2015. All included patients were randomly assigned into the training and validation sets. Univariate and multivariate Cox analysis were performed to identify independent prognostic factors of MBC. These essential prognostic variables were combined to construct nomogram models to predict overall survival (OS) and cancer-specific survival (CSS) in patients with MBC. Model performance was evaluated by concordance index (C-index) and calibration plots.ResultsA total of 1835 patients were collected and divided into the training (1223) and validation (612) groups. The multivariate Cox model identified age, TNM stage, T stage, and N stage, chemotherapy and radiotherapy as independent covariates associated with OS, while these variables except for age and chemotherapy were independent prognostic factors of CSS. The nomogram constructed based on these covariates demonstrated excellent accuracy in estimating 3-, and 5-year OS and CSS, with a C-index of 0.759 (95% CI, 0.746-0.772) for OS and 0.766 (95% CI, 0.751-0.781) for CSS in the training cohort. In the validation cohort, the nomogram-predicted C-index was 0.754 for OS (95%CI, 0.734-0.774) and 0.752 (95%CI, 0.728-0.776) for CSS. All calibration curves exhibited good consistency between predicted and actual survival.ConclusionsThese nomogram models established in this study can help to enhance the accuracy of prognostic prediction, which may thereby improve individualized assessment of survival risks and facilitate to provide constructive therapeutic suggestions.
Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort

Xiao Huang,Zhou Luo,Wei Liang,Guojian Xie,Xusen Lang,Jiaxiang Gou,Chenxiao Liu,Xiangnan Xu,Deyuan Fu

DOI: https://doi.org/10.1245/s10434-022-11911-8

IF: 4.339

2022-06-04

Annals of Surgical Oncology

Abstract:Young breast cancer (YBC) patients are more prone to lymph node metastasis than other age groups. Our study aimed to investigate the predictive value of lymph node ratio (LNR) in YBC patients and create a nomogram to predict overall survival (OS), thus helping clinical diagnosis and treatment.

oncology,surgery
Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3

Jiawei Wang,Lili Chen,Yan Nie,Wei Wu,Yandan Yao

DOI: https://doi.org/10.1016/j.clbc.2020.06.002

IF: 3.078

2020-12-01

Clinical Breast Cancer

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Breast cancer patients with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The eligible patients from the Surveillance, Epidemiology and End Results (SEER) database were randomly divided into training and validation cohorts. Chi-square tests and survival curves were performed to define the consistency between these two cohorts. Univariate and multivariate logistic regressions were carried out to identify the independent clinicopathological factors of pN3 breast cancer patients. A nomogram was developed and validated internally and externally by a calibration curve and compared with the 7th edition American Joint Committee on Cancer (AJCC) TNM staging classification in discrimination ability.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Race, age at diagnosis, marital status, grade, T stage, N stage, breast cancer subtype, surgery, radiotherapy, and chemotherapy were independent predictive factors of OS in pN3 breast cancer. We developed a nomogram to predict 1, 3, and 5 year OS and further validated it in both cohorts, demonstrating better prediction capacity in OS than that of the 7th edition AJCC TNM staging classification (AUC in ROC curve:0.745 and 0.611 in the training cohort, 0.768 and 0.624 in the validation cohort, respectively).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>We have developed and validated the first nomogram for predicting the survival of pN3 breast cancer. This nomogram accurately and reliably predicted the OS of pN3 breast cancer patients. However, more prognostic factors need to be further explored to improve the nomogram.</p>

oncology
A Reliable Nomogram for Predicting Overall Survival in Patients with Triple-Negative Breast Cancer

M. Ma,X. S. Gao,N. Jing

DOI: https://doi.org/10.1016/j.ijrobp.2018.07.1653

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:Background: Currently, there is no reliable nomogram to predict overall survival (OS) for patients with triple-negative breast cancer (TNBC). The purpose of this study was to develop a prognostic nomogram from a cohort of TNBC patients by correlating clinical characteristics and pathological parameters with OS. Methods: We retrospectively analysed 242 eligible TNBC patients treated between 2009 and 2012 at our institution. Age, family history, menopause status, operative type, tumour size, tumour histological grade, the number of axillary metastatic lymph node, postoperative pathological TNM stage, vascular invasion, perineural invasion, CK5/6 expression status, Ki67 index, and E-cadherin expression status were analysed. Predictors were used in a multivariable logistic regression analysis to develop a nomogram that predicts OS. The predictive accuracy and discriminative ability of the nomogram were determined by the concordance index (C-index) with calibration curves, and the receiver operating characteristic (ROC) curves, respectively. Analyses were performed with SPSS and R statistical software packages. Results: The median follow-up time was 70.73 months (range, 7.20–95.93 months) and the median age was 51 years (range, 29–69 years). Of the study patients, 32.6%, 42.6%, and 24.8% had disease stage I, II, III, respectively. The 3- and 5-year OS for all patients were 86.5% (95% CI, 82.2–90.8%) and 81.1% (95% CI, 76.2–86.0%), respectively. Multivariate analyses demonstrated that age, tumour size, the number of axillary metastatic lymph nodes, and E-cadherin expression were independent risk factors for OS. These predictors were used in the nomogram to estimate the 3- and 5-year OS. Calibration curves for probabilities showed good agreement between prediction by the nomogram and actual observation (C-index = 0.821). Conclusions: Using clinicopathological information, we produced a prognostic nomogram that accurately predicts the 3- and 5-year OS for patients with TNBC. Legal entity responsible for the study: Xian-shu Gao. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
A Population-Based Research Utilized a Risk Stratification Model to Forecast the Overall Survival of Young Women With Diagnosed Stage IV Breast Cancer

Wei Tang,Minjing Shao,Wenjun Fang,Jiaqi Wang,Deyuan Fu

DOI: https://doi.org/10.1016/j.clbc.2023.09.001

IF: 3.078

2023-09-23

Clinical Breast Cancer

Abstract:Background The goal of this study is to develop a risk prediction model for estimating overall survival (OS) in young females diagnosed with stage IV breast cancer. Methods The clinical information was retrieved from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. To identify the dependent risk factors, we utilized the Cox proportional hazards regression model in both single and multivariate analyses. We then created a new nomogram to predict the 1-, 3-, and 5-year overall survival probability for these patients based on the identified risk factors. Results Six hundred seventy-six patients who met the eligibility requirements were stochastically partitioned into training (n = 475) and validation (n = 201) groups in a 7:3 ratio. Histology, breast subtype, T classification, brain metastasis, bone metastasis, liver metastasis , and surgery were identified as independent prognostic factors for cancer. To predict the 1-, 3-, and 5-year overall survival (OS) probabilities, all of these independent factors were incorporated into nomograms. Our nomogram demonstrated a favorable discriminatory power, as evidenced by a C-index of 0.737 (95% CI: 0.708-0.766) and 0.717 (95% CI: 0.664-0.770) for the training and validation cohorts, respectively. The calibration curves showed satisfactory consistency in both cohorts. Using this nomogram, we developed a risk stratification model that categorized patients into low-, intermediate-, and high-risk groups. Conclusion The prediction model was more precisely to predict the OS of young females with stage IV breast cancer and could enable individualized risk estimation that could be conducive to physicians exploring therapeutic strategies for effectiveness.

oncology
Construction and validation of a nomogram for predicting the prognosis of breast cancer patients who received adjuvant therapy: an analysis based on the SEER database

Qingliang Jiang,Xianglin Liu,Yuting Wu,Jiaqi Du,Yingying Rao,Jiayu Li,Hengyu Li

DOI: https://doi.org/10.21037/gs-23-537

2024-06-30

Abstract:Background: Breast cancer is the most common malignant tumor in women globally. Despite advances in primary treatment, the role of adjuvant therapy in reducing recurrence and improving survival is critical; however, there is a notable lack of tailored prognostic models for patients receiving adjuvant therapy. This study used the Surveillance, Epidemiology, and End Results (SEER) database to develop a prognostic nomogram for breast cancer patients receiving adjuvant therapy. Methods: The data of breast cancer patients who received adjuvant therapy after surgery in 2014-2015 were extracted from the SEER database. Univariate Cox regression identified significant prognostic variables that were further refined by least absolute shrinkage and selection operator (LASSO) regression and cross-validation analyses. These variables were incorporated into a multivariate Cox regression analysis to establish the predictive model. This model was visualized and validated using various statistical measures. Results: A total of 54,960 patients were included in the study, with 38,472 in the training set and 16,488 in the validation set. Age, sex, race, marital status, grade, tumor (T) stage, lymph node (N) stage, subtype, and radiotherapy were found to be significant independent risk factors of 1-, 3-, and 5-year overall survival (OS). The receiver operating characteristic curve area for 1-, 3-, and 5-year OS was >0.76 in both sets. The consistency index values were 0.768 and 0.763 for the training and validation sets, respectively. The calibration curves showed good fit, and the nomogram exhibited substantial clinical utility. Conclusions: Incorporating various significant factors, the constructed nomogram was able to effectively predict the prognosis of breast cancer patients who received adjuvant therapy. This nomogram extends understandings of complex prognosis scenarios. In addition, it could enhance personalized treatment plans and assist in patient counseling.
Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis

Min-Hao Lyu,You-Zhao Ma,Pei-Qi Tian,Hui-Hui Guo,Chao Wang,Zhen-Zhen Liu,Xiu-Chun Chen

DOI: https://doi.org/10.1097/cm9.0000000000001755

IF: 6.133

2021-11-05

Chinese Medical Journal

Abstract:BACKGROUND: Breast cancer patients with ipsilateral supraclavicular lymph node metastasis (ISLNM) but without distant metastasis are considered to have a poor prognosis. This study aimed to develop a nomogram to predict the overall survival (OS) of breast cancer patients with ISLNM but without distant metastasis.METHODS: Medical records of breast cancer patients who received surgical treatment at the Affiliated Cancer Hospital of Zhengzhou University, Jiyuan People's Hospital and Huaxian People's Hospital between December 21, 2012 and June 30, 2020 were reviewed retrospectively. Overall, 345 patients with pathologically confirmed ISLNM and without evidence of distant metastasis were identified. They were further randomized 2:1 and divided into training (n = 231) and validation (n = 114) cohorts. A nomogram to predict the probability of OS was constructed based on clinicopathologic variables identified by the univariable and multivariable analyses. The predictive accuracy and discriminative ability were measured by calibration plots, concordance index (C-index), and risk group stratification.RESULTS: Univariable analysis showed that estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-positive (HER2+) with Herceptin treatment, and a low axillary lymph node ratio (ALNR) were prognostic factors for better OS. PR+, HER2+ with Herceptin treatment, and a low ALNR remained independent prognostic factors for better OS on multivariable analysis. These variables were incorporated into a nomogram to predict the 1-, 3-, and 5-year OS of breast cancer patients with ISLNM. The C-indexes of the nomogram were 0.737 (95% confidence interval [CI]: 0.660-0.813) and 0.759 (95% CI: 0.636-0.881) for the training and the validation cohorts, respectively. The calibration plots presented excellent agreement between the nomogram prediction and actual observation for 3 and 5 years, but not 1 year, OS in both the cohorts. The nomogram was also able to stratify patients into different risk groups.CONCLUSIONS: In this study, we established and validated a novel nomogram for predicting survival of patients with ISLNM. This nomogram may, to some extent, allow clinicians to more accurately estimate prognosis and to make personalized therapeutic decisions for individual patients with ISLNM.

medicine, general & internal
Assessment of geriatric and clinical domains for development and validation of a novel nomogram to predict the prognosis of older patients with breast cancer: a real-world retrospective cohort study

Yan Lin,Yu Song,Ying Xu,Changjun Wang,Yali Xu,Xin Huang,Qiang Sun

DOI: https://doi.org/10.3389/fonc.2023.1250927

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:BackgroundBreast cancer is a relatively heterogeneous disease in the older population. Survival in older breast cancer patients is not only affected by tumor-related factors, but also by geriatric assessment domains. How tumor clinical factors and geriatric factors specifically affect the survival rate of older patients and how to combine these two factors to predict the risk of death in older patients with breast cancer remain clinical questions to be addressed.MethodWe used the Peking Union Medical College Hospital database to identify older patients (>= 65 years) who were newly diagnosed with breast cancer between January 2013 and December 2019. Of the 641 eligible patients, we retrospectively analyzed the clinical and geriatric data of 556 patients who formed our study population. The primary outcomes were overall survival (OS) and breast cancer-specific survival (BCSS). Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors and construct a nomogram to predict the 1-, 3-, and 5-year survival rates. The performance of the constructed nomogram was evaluated using calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).ResultsMultivariate Cox regression analysis revealed seven independent prognostic factors associated with OS in older patients with breast cancer: age, tumor stage, lymph node stage, intrinsic molecular subtype, functional status, comorbidities, and psychological state. Nomogram based on these seven factors yielded excellent performance, with area under the ROC curve (AUROC) of 0.748. Similarly, the nomogram for BCSS had an AUROC of 0.760. Moreover, the calibration curve and DCA revealed good predictive accuracy between the actual and predicted probabilities.ConclusionIndependent prognostic factors for OS and BCSS in older patients with breast cancer in China were determined in our study. A novel nomogram for predicting the 1-, 3-, and 5-year OS and BCSS in this patient population was developed and validated. The nomogram exhibited good accuracy, indicating its potential for clinical decision making and improving outcomes.
Development and External Validation of a Clinical Nomogram for Individually Predicting Survival of Metaplastic Breast Cancer

Jiani Wang,Qing Li,Yang Luo,Yiqun Han,Fei Ma,Ruigang Cai,Qiao Li,Ying Fan,Jiayu Wang,Pin Zhang,Binghe Xu

DOI: https://doi.org/10.1016/j.clbc.2022.06.006

IF: 3.078

2022-08-11

Clinical Breast Cancer

Abstract:Background Few studies have concerned the prognosis of metaplastic breast cancer (MpBC), a rare and diverse malignancy. A prognostic index estimating the MpBC survival would be attractive in clinical practice. Patients and Methods We retrospectively analyzed MpBC patients from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic factors were identified and the final nomogram was developed to predict the 1-, 3-, or 5-year overall survival (OS). Calibration curves were provided to internally validate the performance of the nomogram and discriminative ability was appraised by concordance index (C-index). Results A total of 1017 MpBC patients diagnosed between 2010 and 2015 were assigned into 3:1 as training set (n = 763) and SEER validation set (n = 254). An external validation was performed by an individual set of 94 MpBC patients from National Cancer Center in China from 2010 to 2018. The nomogram finally consisted of 7 independent prognostic factors and presented a good accuracy for predicting the OS with the C-index of 0.77 (95% CI: 0.751-0.786). Interestingly, the nomogram based on the western (including 92.5% non-Asian) SEER validation population (C-index of nomogram: 0.76, 95% CI: 0.737-0.796) also has an optimal discrimination in Asian population (C-index of nomogram: 0.70). The calibration plots of the nomogram predictions were also accurate and corresponded closely with the actual survival rates. Conclusion This novel nomogram was accurate enough to predict the OS by using readily available clinicopathologic factors in MpBC general population, which could provide individualized recommendations for patients and clinical decisions for physicians.

oncology
Development and validation of a nomogram in survival prediction among advanced breast cancer patients

Jianli Zhao,Yaping Yang,Danmei Pang,Yunfang Yu,Xiao Lin,Kai Chen,Guolin Ye,Jun Tang,Qian Hu,Jie Chai,Zhuofei Bi,Linxiaoxiao Ding,Wenjing Wu,Yinduo Zeng,Xiujuan Gui,Donggeng Liu,Herui Yao,Ying Wang

DOI: https://doi.org/10.21037/atm-20-3473

IF: 3.616

2020-11-01

Annals of Translational Medicine

Abstract:BACKGROUND: The overall survival (OS) among patients with advanced breast cancer (ABC) varies greatly. Although molecular subtype is known as the most important factor in OS differentiation, significant differences in OS among patients with the same molecular subtype still occur, leading to the need for a more accurate prognostic prediction model. This study aimed to develop a prediction model (nomogram) based on current diagnosis and treatment to predict the OS of newly diagnosed ABC patients in China.METHODS: From the institution's database, we collected data of 368 ABC patients from Sun Yat-sen Memorial Hospital (national hospital) as a training set to establish a nomogram with prognostic risk factors that calculated the predicted probability of survival. Nomograms were independently validated with 278 patients with ABC from two other institutions using the concordance index (C-index), calibration plots and risk group stratifications.RESULTS: The initial primary tumor stage, molecular subtype, disease-free survival (DFS), presence of brain metastasis, and the tumor burden of metastasis disease (local recurrence, oligo-metastatic disease, or multiple-metastatic disease) were included in the prognostic nomogram. The nomogram had a C-index of 0.77 and 0.71 in the training and the validation sets, respectively. The nomogram was able to stratify patients into different risk groups, respectively (HR 6.81, 95% CI: 4.69 to 9.89, P<0.001). In the lower risk score group (risk score <11), there was no significant difference between the OS with chemotherapy and hormone therapy (HR 0.81, 95% CI: 0.44 to 1.47, P=0.48).CONCLUSIONS: We have constructed a novel prediction nomogram that can guide the physicians to select personalized treatment options. Furthermore, our study is the first to add oligo-metastatic disease and primary endocrine/trastuzumab resistance into the prognostic models.

oncology,medicine, research & experimental
Prospects of immunotherapy for the treatment of prostate carcinoma--a review.

G. Hillman,J. Triest,M. Cher,S. V. Kocheril,B. Talati

DOI: https://doi.org/10.1046/J.1525-1500.1999.99027.X

Cancer Detection and Prevention

Abstract:The treatment of prostate carcinoma is dependent on the stage of the disease. Patients who present with clinically localized cancer or locally advanced tumors can be potentially cured by radical prostatectomy, radiation, and hormonal therapy. However, disease progression can occur in 30-50% of patients diagnosed with clinically localized cancer. The bone is the predominant site of metastases. Metastatic prostate cancer is first treated by androgen blockade but within a few months becomes hormone refractory. Hormone refractory metastatic prostate cancer is not responsive to conventional treatments, and patients have an expected survival of less than a year. It is essential to develop new approaches for the treatment of hormone refractory metastatic disease. Immunotherapy, based on enhancement of the host immune response against the tumor, has been used as an alternative therapy for the treatment of metastatic cancers refractory to conventional therapy in particular for melanoma and renal cell carcinoma. In this review, we will summarize various immunotherapeutic approaches developed over the last 18 years, and we will address the potential of immunotherapy for the treatment of metastatic prostate carcinoma by reviewing preclinical studies and initial clinical trials performed in this field.
Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study

Fangxu Yin,Song Wang,Chong Hou,Yiyuan Zhang,Zhenlin Yang,Xiaohong Wang

DOI: https://doi.org/10.3389/fpubh.2022.969030

IF: 5.2

2022-09-20

Frontiers in Public Health

Abstract:Background For patients with locally advanced breast cancer (LABC), conventional TNM staging is not accurate in predicting survival outcomes. The aim of this study was to develop two accurate survival prediction models to guide clinical decision making. Methods A retrospective analysis of 22,842 LABC patients was performed from 2010 to 2015 using the Surveillance, Epidemiology and End Results (SEER) database. An additional cohort of 200 patients from the Binzhou Medical University Hospital (BMUH) was analyzed. The least absolute shrinkage and selection operator (LASSO) regression was used to screen for variables. The identified variables were used to build a survival prediction model. The performance of the nomogram models was assessed based on the concordance index (C-index), calibration plot, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). Results The LASSO analysis identified 9 variables in patients with LABC, including age, marital status, Grade, histological type, T-stage, N-stage, surgery, radiotherapy, and chemotherapy. In the training cohort, the C-index of the nomogram in predicting the overall survival (OS) was 0.767 [95% confidence intervals (95% CI): 0.751–0.775], cancer specific survival (CSS) was 0.765 (95% CI: 0.756–0.774). In the external validation cohort, the C-index of the nomogram in predicting the OS was 0.858 (95% CI: 0.812–0.904), the CSS was 0.866 (95% CI: 0.817–0.915). In the training cohort, the area under the receiver operator characteristics curve (AUC) values of the nomogram in prediction of the 1, 3, and 5-year OS were 0.836 (95% CI: 0.821–0.851), 0.769 (95% CI: 0.759–0.780), and 0.750 (95% CI: 0.738–0.762), respectively. The AUC values for prediction of the 1, 3, and 5-year CSS were 0.829 (95% CI: 0.811–0.847), 0.769 (95% CI: 0.757–0.780), and 0.745 (95% CI: 0.732–0.758), respectively. Results of the C-index, ROC curve, and DCA demonstrated that the nomogram was more accurate in predicting the OS and CSS of patients compared with conventional TNM staging. Conclusion Two prediction models were developed and validated in this study which provided more accurate prediction of the OS and CSS in LABC patients than the TNM staging. The constructed models can be used for predicting survival outcomes and guide treatment plans for LABC patients.

public, environmental & occupational health
Establishment and validation of an ultrasound-based nomogram with risk stratification for short disease-free survival in breast cancer

Qiang Guo,Zhiwu Dong,Lixin Jiang,Lei Zhang,Ziyao Li,Dongmo Wang

DOI: https://doi.org/10.1002/jcu.23296

Abstract:Purpose: This retrospective study aimed to develop and validate an Ultrasound (US)-based nomogram to predict short disease-free survival (short-DFS, less than 120 months DFS) in breast cancer (BC). Methods: Nomogram was established based on a training data of 311 BC patients by multivariable logistic regression, and were assessed by discrimination, calibration, and clinical usefulness. Risk stratification was performed by X-tile. An independent testing data of 200 patients with BC was used for external validation. Results: Nine predictors including three US features and six clinical parameters were screened into the nomogram by Lasso (log λ = -3.594) in training data. Better performance was obtained in the training data (C-index: 0.942) and testing data (C-index: 0.914). Calibration analysis indicated optimal agreement between nomogram predictions and actual observations (p = 0.67). Decision curve analysis showed a great clinical benefit (Youden index: 0.634). Three risk levels are low-risk (<184.0), moderate-risk (184.0-345.3) and high-risk (>345.3). Our nomograms had larger area under the receiver operating characteristic (ROC) curves compared with Magee Equation and Nottingham Prognostic models (0.942 vs. 0.824, 0.790). Conclusion: The US-based nomogram and the practical score system facilitate individualized prediction of short-DFS to optimize clinical decisions and improve prognosis in patients with BC.

Evaluation of anesthetic technique on surgical site infections (SSIs) at a single institution.

A Nomogram and Risk Stratification System for Predicting Survival in T1-2N0-1 Breast Cancer Patients with Liver Metastasis in Females: a Population-Based Study

Development and Validation of Nomograms for Predicting Overall and Breast Cancer–Specific Survival in Young Women with Breast Cancer: A Population-Based Study

Establishment and Verification of Prognostic Nomograms for Young Women with Breast Cancer Bone Metastasis

Nomograms predict survival in elderly women with triple-negative breast cancer: A SEER population-based study

Development and Validation of Nomograms for Predicting Overall and Cancer-Specific Survival in Young Patients with Non-Small Cell Lung Cancer

Overall survival and disease‐free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms

Nomogram for Predicting Survival in Triple-Negative Breast Cancer Patients with Histology of Infiltrating Duct Carcinoma: a Population-Based Study.

Novel Nomograms to Predict of Overall Survival and Cancer-specific Survival of Patients of Metaplastic Breast Cancer

Survival Nomogram for Young Breast Cancer Patients Based on the SEER Database and an External Validation Cohort

Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3

A Reliable Nomogram for Predicting Overall Survival in Patients with Triple-Negative Breast Cancer

A Population-Based Research Utilized a Risk Stratification Model to Forecast the Overall Survival of Young Women With Diagnosed Stage IV Breast Cancer

Construction and validation of a nomogram for predicting the prognosis of breast cancer patients who received adjuvant therapy: an analysis based on the SEER database

Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis

Assessment of geriatric and clinical domains for development and validation of a novel nomogram to predict the prognosis of older patients with breast cancer: a real-world retrospective cohort study

Development and External Validation of a Clinical Nomogram for Individually Predicting Survival of Metaplastic Breast Cancer

Development and validation of a nomogram in survival prediction among advanced breast cancer patients

Prospects of immunotherapy for the treatment of prostate carcinoma--a review.

Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study

Establishment and validation of an ultrasound-based nomogram with risk stratification for short disease-free survival in breast cancer